1. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment];Besarab;New Engl J Med,1998
2. FDA FDA Advisory Committee Briefing Document; Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee; and Errata http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-02-FDA-Errata%20.pdf
3. The normal hematocrit study- follow-up;Besarab;New Engl J Med,2007
4. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease;KDOQI;Am J Kidney Dis,2006
5. Correction of anemia with epoetin alfa in chronic kidney disease;Singh;N Engl J Med,2006